SEC Form 4 · accession 0000921895-17-001278
Enveric Biosciences, Inc. · ENVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dimitrios Angelis
Director
Period of report
May 1, 2017
Accepted (ET)
May 3, 2017 · 6:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000890821
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 1, 2017 | M | 9,140 | — | A | 17,663 | D | |
| Common StockF2,F3 | May 1, 2017 | F | 3,199 | $6.59 | D | 14,464 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1 | — | May 1, 2017 | M | 9,140 | A | — | — | Common Stock | 9,140 | 0 | D |
Explanation of responses
- F1Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person.
- F2Represents number of shares withheld by the Issuer for the payment of taxes. No shares of Common Stock were sold by the Reporting Person in connection with this transaction. The Reporting Person will retain the net number of shares issued upon the settlement of the RSUs.
- F3Closing market price of the Issuer's common stock on the transaction date.